1-20 of 28
Gabrielle T. Prince
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo
Journal: Blood
Blood (2023) 142 (Supplement 1): 3582.
https://doi.org/10.1182/blood-2023-191047
Published: 2023
Journal Articles

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Sergiu Pasca, Saurav D. Haldar, Alexander J. Ambinder, Jonathan Webster, Tania Jain, William Brian Dalton, Gabrielle T. Prince, Gabriel Ghiaur, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Cory Schulz, Kristin Stokvis, Mark J. Levis, Richard J. Jones, Lukasz P. Gondek
Journal: Blood
Blood (2022) 140 (Supplement 1): 10629–10631.
https://doi.org/10.1182/blood-2022-169148
Published: 2022
Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Jonathan Allen Webster, Madison C. Reed, Hua-Ling Tsai, Alexander J. Ambinder, Tania Jain, Amy E. DeZern, Mark J. Levis, Margaret M. Showel, Gabrielle T. Prince, Christopher S. Hourigan, Javier Bolaños-Meade, Lukasz P. Gondek, Gabriel Ghiaur, William Brian Dalton, Suman Paul, Ephraim J. Fuchs, Christian B. Gocke, Abbas Abbas Ali, Douglas E. Gladstone, Carol Ann Huff, Ivan M. Borrello, Lode J. Swinnen, Nina D. Wagner-Johnston, Richard F. Ambinder, Leo Luznik, Ivana Gojo, B. Douglas Douglas Smith, Ravi Varadhan, Richard J. Jones, Philip H. Imus
Journal: Blood
Blood (2022) 140 (Supplement 1): 4813–4815.
https://doi.org/10.1182/blood-2022-171038
Published: 2022
Journal Articles

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Matthew Scarlotta, Jonathan Webster, Matthew Newman, Cory Schulz, Kristin Stokvis, Alexander J. Ambinder, Tania Jain, William Brian Dalton, Lukasz P. Gondek, Gabrielle T. Prince, Gabriel Ghiaur, Christopher S. Hourigan, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Mark J. Levis
Journal: Blood
Blood (2022) 140 (Supplement 1): 11747–11748.
https://doi.org/10.1182/blood-2022-160300
Published: 2022
Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Jonathan Webster, B. Douglas Smith, Amy E. DeZern, Alexander J. Ambinder, Mark Levis, Margaret M. Showel, Gabrielle T. Prince, Lukasz P. Gondek, Gabriel Ghiaur, William Brian Dalton, Christopher S. Hourigan, Tania Jain, Douglas E Gladstone, Leo Luznik, Philip H. Imus, Javier Bolanos-Meade, Ephraim J. Fuchs, Christian B. Gocke, Abbas Abbas Ali, Carol Ann Huff, Ivan M. Borrello, Lode J. Swinnen, Nina D. Wagner-Johnston, Richard F. Ambinder, Richard J. Jones, Ivana Gojo
Journal: Blood
Blood (2021) 138 (Supplement 1): 1846.
https://doi.org/10.1182/blood-2021-153750
Published: 2021
Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Jonathan Webster, MD, Leo Luznik, MD, Hua-Ling Tsai, ScM, Philip H. Imus, MD, Amy E. DeZern, MD, Keith W. Pratz, MD, Mark Levis, MD PhD, Ivana Gojo, MD, Margaret M. Showel, MD, Gabrielle T. Prince, MD, Javier Bolanos-Meade, MD, Lukasz P. Gondek, MDPhD, Gabriel Ghiaur, MD PhD, William Brian Dalton, MD PhD, Tania Jain, MD, Ephraim J. Fuchs, MD MBA, Douglas E Gladstone, MD, Christian B. Gocke, MD PhD, Abbas Abbas Ali, MD, Carol Ann Huff, MD, Ivan M. Borrello, MD, Lode J. Swinnen, MB ChB, Nina D. Wagner-Johnston, Richard F. Ambinder, MD, Richard J. Jones, MD, B. Douglas Smith, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141294
Published: 2020
Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Jonathan Webster, MD, Hua-Ling Tsai, ScM, Eric Gehrie, Tania Jain, MD, Christopher S. Hourigan, MDDPhil, William Brian Dalton, MD PhD, Gabrielle T. Prince, MD, Lukasz P. Gondek, MDPhD, Gabriel Ghiaur, MD PhD, Amy E. DeZern, MD, Margaret M. Showel, MD, Ivana Gojo, MD, Douglas E Gladstone, MD, Philip H. Imus, MD, Javier Bolanos-Meade, MD, Leo Luznik, MD, Ephraim J. Fuchs, MD MBA, Christian B. Gocke, MD PhD, Abbas Abbas Ali, MD, Carol Ann Huff, MD, Ivan M. Borrello, MD, Lode J. Swinnen, MB ChB, Nina D. Wagner-Johnston, Richard F. Ambinder, MD, Richard J. Jones, MD, B. Douglas Smith, MD, Mark Levis, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-141264
Published: 2020
Journal Articles

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Sung Choe, PhD, Hongfang Wang, PhD, Gail J. Roboz, MD, Courtney D. DiNardo, MD MSCE, Eytan M. Stein, MD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Justin M. Watts, MD, Bin Fan, PhD, Parham Nejad, BSc, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD, Richard M. Stone, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136589
Published: 2020
Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Clinical Trials & Observations
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, Will Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A. Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar, Richard M. Stone
Journal: Blood
Blood (2020) 135 (7): 463–471.
https://doi.org/10.1182/blood.2019002140
Published: 2020
Includes: Supplemental data
Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 832.
https://doi.org/10.1182/blood-2019-127345
Published: 2019
Journal Articles

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Jonathan Webster, MD, Richard F. Ambinder, MD, Richard J. Jones, MD, Nina D. Wagner-Johnston, MD, Gabrielle T. Prince, MD, Audra Shedeck, CRNP, Amanda Blackford, MS, Leo Luznik, MD, Ivana Gojo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 778.
https://doi.org/10.1182/blood-2019-128255
Published: 2019
Journal Articles

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Bryan Hambley, MD, Eric Gehrie, Jonathan Webster, MD, Margaret M. Showel, MD, Lukasz P. Gondek, MD PhD, William Brian Dalton, MD PhD, Gabrielle T. Prince, MD, Douglas E Gladstone, MD, Ivana Gojo, MD, Gabriel Ghiaur, MD PhD, Keith W. Pratz, MD, B. Douglas Smith, MD, Amy E. DeZern, MD, Mark J. Levis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3841.
https://doi.org/10.1182/blood-2019-123229
Published: 2019
Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

James M. Foran, MD, Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony Stein, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Abdulafeez Oluyadi, PharmD, Thomas Winkler, MD, Denice Hickman, BSN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4254.
https://doi.org/10.1182/blood-2019-123946
Published: 2019
Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Sonia Esparza, MD, Anastasia Ivanova, PhD, Dominic T. Moore, MPH, MS, Matthew C Foster, MD, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik W. Van Deventer, MD, Laura Blanchard, William Churchwell, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Ashley Reed, Nancy Vogler, Jonathan Webster, MD, Gabrielle T. Prince, MD, Amy E. DeZern, MD, B. Douglas Smith, MD, Mark J. Levis, MD, Leo Luznik, MD, Jonathan S Serody, MD, Ivana Gojo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 831.
https://doi.org/10.1182/blood-2019-126065
Published: 2019
Journal Articles

Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)

Joshua F Zeidner, MD, Hanna Knaus, MD, Amer M. Zeidan, MBBS, MHS, Amanda Blackford, Raul Montiel-Esparza, MD, Gabrielle T. Prince, MD, Lukasz P. Gondek, MD PhD, Gabriel Ghiaur, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Keith W. Pratz, MD, B. Douglas Smith, MD, Mark J. Levis, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Howard Streicher, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 335.
https://doi.org/10.1182/blood-2018-99-114961
Published: 2018
Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

Jonathan Webster, MD, Marlise R. Luskin, MD, Gabrielle T. Prince, MD, Amy E. DeZern, MD, Daniel J. DeAngelo, MD, Mark J. Levis, MD, Amanda Blackford, Elad Sharon, MD MPH, Howard Streicher, MD, Leo Luznik, MD, Ivana Gojo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 557.
https://doi.org/10.1182/blood-2018-99-111845
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Gail J. Roboz, MD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Jessica K. Altman, MD, Martha L. Arellano, MD, William B. Donnellan, MD, Harry P. Erba, MD PhD, Gabriel N. Mannis, MD, Daniel A Pollyea, MD, Anthony S. Stein, MD, Geoffrey L. Uy, MD, Justin M. Watts, MD, Amir T. Fathi, MD, Hagop M. Kantarjian, MD, Martin S. Tallman, MD, Sung Choe, PhD, David Dai, PhD, Bin Fan, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Hua Liu, PhD, Samuel V. Agresta, MD, Bin Wu, PhD, Eyal C. Attar, MD, Richard M. Stone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 561.
https://doi.org/10.1182/blood-2018-99-110595
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony S. Stein, MD, James M. Foran, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, David Dai, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1812.
https://doi.org/10.1182/blood-2018-99-111264
Published: 2018
Journal Articles

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Courtney D. DiNardo, MDMSc, Stephane De Botton, Eytan M. Stein, MD, Gail J. Roboz, MD, Alice S. Mims, MD MSCR, Daniel A. Pollyea, MD, Ronan T. Swords, MD PhD FRCPI, FRCPath, Jessica K. Altman, MD, Robert H. Collins, MD, Gabriel N. Mannis, MD, Geoffrey L. Uy, MD, Will Donnellan, MD, Arnaud Pigneux, MD PhD, Amir T. Fathi, MD MD BS, Anthony S. Stein, MD, Harry P. Erba, MD PhD, Gabrielle T. Prince, MD, James M. Foran, MD, Elie Traer, MD PhD, Robert K. Stuart, MD, Martha L. Arellano, MD, James L. Slack, MD, Mikkael A. Sekeres, MD MS, Katharine Yen, Stephanie M. Kapsalis, Hua Liu, Meredith Goldwasser, Sam Agresta, MD, Eyal C. Attar, MD, Martin S. Tallman, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 725.
https://doi.org/10.1182/blood.V130.Suppl_1.725.725
Published: 2017
Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Melanie Rebechi, Amy E. DeZern, MD, Amanda Kagan, MD, B. Douglas Smith, MD, Ivana Gojo, MD, Margaret M. Showel, MD, Gabrielle T. Prince, MD, Gabriel Ghiaur, MD PhD, Lukasz P. Gondek, MD PhD, William Matsui, MD, Ephraim J. Fuchs, MD MBA, Leo Luznik, MD, Shannon R. McCurdy, MD, Carol Ann Huff, MD, Lode J. Swinnen, Ivan M. Borrello, MD, Douglas E. Gladstone, MD, Javier Bolanos-Meade, MD, Richard F Ambinder, MD, Richard J. Jones, MD, Mark J. Levis, MD, Keith Pratz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2593.
https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593
Published: 2017